

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/593,691-Conf. #3128
				Filing Date	December 4, 2006
				First Named Inventor	Ayumu KURIMOTO
				Art Unit	1624
				Examiner Name	M. L. Berch
Sheet	1	of	3	Attorney Docket Number	0020-5516PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-2002/0068745A1	06-2002	Levy et al	
	AB*	US-2006/0252774A1	06-2002	Levy et al	
	AC*	US-2007/0225303	09-2007	Ogita	
	AD*	US-2005/54590	03-2005	Averette	
	AE*	US-2004/0132748A1	07-2004	Isobe	
	AF*	US-2009/0192153A1	07-2009	Hashimoto et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	BA	EP-1908480-A1	04-09-2008	Riken		
	BB	JP-10-501533A1	02-10-1998	Biochem Pharm.		Abs
	BC	JP-10-507474	07-14-1998	Chiron Corp.		Abs
	BD	JP-2007-504282				
	BE	JP-047422				Abs
	BF	JP-0-867449				Abs
	BG	JP-0-367451				Abs
	BH	WO-1999/04448-A1	04-15-1999	Japan Energy Corp.		Abs
	BI	WO-2002/005095-A1	10-04-2002	Japan Energy Corp.		Abs
	BJ	WO-2006/129784-A1	12-07-2006	Riken		Abs
	BK	WO-2004/014481				Abs
	BL	WO-2004/029054	04-08-2004			Abs
	BM	WO-2005/002092-A1	10-06-2005	Sumitomo Pharma et al.		Abs
	BN	WO-2005/002893-A1	10-06-2005	Sumitomo Pharma et al.		Abs
	BO	WO-2006/117670-A1	11-09-2006	Pfizer Ltd et al		
	BP	WO-2007/024707-A2	03-01-2007	Univ California et al		
	BQ	WO-2007/031726	03-2007			
	BR	WO-2007/034173	03-2007			

Examiner Signature	/Mark Berch/ (07/06/2010)	Date Considered	
--------------------	---------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.B./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/593,691-Conf. #3128
				Filing Date	December 4, 2006
				First Named Inventor	Ayumu KURIMOTO
				Art Unit	1624
				Examiner Name	M. L. Berch
Sheet	2	of	3	Attorney Docket Number	0020-5516PUS1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BS	WO-2007/034817-A1	03-29-2007	Dainippon Sumitomo Pharma Co et al.		Ab
	BT	WO-2007/034881-A1	03-29-2007	Dainippon Sumitomo Pharma Co et al.		
	BU	WO-2007/034882-A1	03-29-2007	Dainippon Sumitomo Pharma Co et al.		
	BV	WO-2007/034916-A1	03-29-2007	Dainippon Sumitomo Pharma Co et al.		
	BW	WO-2007/034917-A1	03-29-2007	Dainippon Sumitomo Pharma Co et al.		Ab
	BX	WO-2008/071976-A1	06-19-2008	Astrazeneca Ab et al.		
	BY	WO-2008/114006-A2	09-25-2008	Astrazeneca Ab et al.		
	BZ	WO-2008/114008-A1	09-25-2008	Astrazeneca Ab et al.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Korc, M., "Pathways for aberrant angiogenesis in pancreatic cancer," Biomed Central, Vol 2, No 8, pp 1-8 (2003)	
	CB	Zalutsky, MR, "Targeted radiotherapy of brain tumours," British J. of Cancer, Vol 90, pp 1469-1473 (2004)	
	CC	Drazen, J.M., "Surgery for Emphysema-Not for Everyone," New Eng. J. Med., Vol 345, No 15, pp 1126-1128 (2001)	
	CD	Mogulkoc, N., et al., "Pulmonary function in Idiopathic Pulmonary Fibrosis and Referral for Lung Transplantation," Am. J. Respir. Crit. Care Med., Vol 164, pp 103-108 (2001)	
	CE	Palmer, S., et al., "Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development," AIDS, Vol 13, pp 661-667 (1999)	
	CF	Fridkin, SK, "Vancomycin-Intermediate and -Resistant <i>Staphylococcus aureus</i> : What the Infectious Disease Specialist Needs to Know," Clinical Infectious Diseases, Vol 32, pp 108-115 (2001)	

Examiner Signature	/Mark Berch/ (07/06/2010)	Date Considered	
-----------------------	---------------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.B./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/593,691-Conf. #3128
				Filing Date	December 4, 2006
				First Named Inventor	Ayumu KURIMOTO
				Art Unit	1624
				Examiner Name	M. L. Berch
Sheet	3	of	3	Attorney Docket Number	0020-5516PUS1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CG	Lee, J., et al., "Activation of anti-hepatitis C virus responses via Toll-like receptor 7," PNAS, Vol 103, No 6, pp 1828-1833 (2006)	
	CH	Kurimoto, A., et al., "Synthesis and Biological Evaluation of 8-Oxoadenine Derivatives as Toll-like Receptor 7 Agonists Introducing the Antedrug Concept," J. Med. Chem., Vol 53, No 7, pp 2964-2972 (2010)	
	CI	2009-03-26 Office Action for Russian Application 2006137706 w/English Translation	
	CJ	2009-08-21 Office Action for Russian Application 2006137706 w/English Translation	
	CK	2009-03-25 New Zealand Examination Report for Application 549903	
	CL	2010-01-14 New Zealand Examination Report for Application 549903	
	CM	2009-11-17 Office Action for Japanese Application 2006-511501 w/English Translation	
	CN	2009-12-10 Office Action for Israeli Application 177518 in English	
	CO	2006-09-26 Office Action for Egypt Application PCT923/2006 w/English Translation	
	CP	2008-04-25 Office Action for Chinese Application 200580009706.3 w/English Translation	
	CQ	2010-01-15 Office Action for Malaysia Application PI20051334 in English	
	CR	2010-03-11 Office Action for US Application 10/594,074	
	CS	2008 PCT/JP2006/318603 IPER for Application 12/067,649	
	CT	2009-09-22 IPER for Application 12/532,007	
	CU	PCT/JP2008/055088 IPER for Application 12/531,867	

Examiner Signature	/Mark Berch/ (07/06/2010)	Date Considered	
-----------------------	---------------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.B./